Launching a medical device requires more than just FDA clearance; it requires a clear path to payment. For your innovative device to succeed commercially, healthcare providers must be able to get reimbursed for using it. AlvaMed offers strategic reimbursement services to help you navigate this complex landscape and secure market access.
We integrate reimbursement strategy early in your development cycle to create a seamless path to market. Our services are tailored to address the unique needs of startups and established companies alike.
We identify the relevant codes, coverage policies, and payment rates for your device’s intended use in key markets.
We help define the clinical and economic evidence required by payers to establish coverage and favorable payment.
Determine the most appropriate current procedural codes (CPT/HCPCS) or advise on the need for new code applications.
Guidance on developing materials for presentations and negotiations with major commercial and government payers.
Crafting compelling economic arguments that demonstrate the value of your device to payers, providers, and patients.
Creating financial models to forecast reimbursement potential and assess the impact of various payment scenarios.
By partnering with AlvaMed for your reimbursement needs, you benefit from:
FDA clearance confirms your device is safe and effective for its intended use, but it doesn’t guarantee payment. A reimbursement strategy is essential because it addresses three critical elements of reimbursement: Coding, Coverage, and Payment. If providers can’t get paid for using your device, its commercial success will be severely limited, regardless of its clinical benefit.
You should start planning your reimbursement strategy as early as the concept or preclinical stage. Delaying this process until after FDA clearance is a common and costly mistake. Integrating reimbursement planning early helps you define the necessary clinical and economic evidence required by payers and ensures your clinical trials are designed to meet both regulatory and coverage needs.
AlvaMed ensures a holistic launch plan by integrating reimbursement discussions with your regulatory and clinical strategies from the start. For example, we identify the specific clinical outcomes or economic evidence payers require, which directly informs the design and endpoints of your regulatory and clinical trials. This prevents costly “redo” studies and ensures the data you collect satisfies both the FDA and key payers
Yes. If your device involves a procedure that is not adequately described by existing codes, securing a new CPT (Current Procedural Terminology) code is a significant part of the reimbursement strategy. AlvaMed can assess the need for a new code and guide you through the entire CPT application process, which involves engaging with the American Medical Association (AMA) CPT Editorial Panel. We help structure the clinical and utilization evidence required to support the application.
Schedule a meeting with Mark Cox to discuss how AlvaMed can help with your reimbursement strategy.
